ASCL2 and central nervous system cancer: As expected, validation studies showed that ROC‐325 significantly decreased the progression of glioma cells with high ASCL2‐ATG9B axis activity, indicating that ROC‐325 has great potential to improve the survival of glioma patients with high expression of the ASCL2‐ATG9B signaling axis (Figure 6M).